Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingMar 12, 2025Nelarabine InjectionFailed Impurities/Degradation SpecificationsZydus Pharmaceuticals (USA) Inc · D-0256-2025Class IIOngoingMar 12, 2025Nelarabine InjectionFailed Impurities/Degradation SpecificationsZydus Pharmaceuticals (USA) Inc · D-0255-2025Class IIOngoingMar 12, 2025Morphine Sulfate 5 mg per 0.25 mL Oral SyringeDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0254-2025Class IIOngoingMar 12, 2025Lorazepam 0.5 mg per 0.25 mL Oral SyringeDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0253-2025Class IIOngoingMar 12, 2025Ferrous Sulfate 7.5 mg Iron/0.5 mL Oral SyringeDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0252-2025Class IIOngoingMar 12, 2025Simethicone 20 mg per 0.3 mL Oral SyringeDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0251-2025Class IIOngoingMar 12, 2025Ergocalciferol - Vitamin D Supplement - 10 mcgDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC · D-0250-2025Class IIOngoingMar 12, 2025Morphine Sulfate Extended-Release TabletsFailed Dissolution SpecificationsSun Pharmaceutical Industries Inc · D-0249-2025Class IITerminatedMar 5, 2025Avastin 1.25 mg/0.05 mL in 0.25 mL SyringeLack of Assurance of Sterility: due to a quality control process deviationTurbare Manufacturing · D-0248-2025Class IIOngoingMar 5, 2025ViaMed Alcohol Prep PadsLack of assurance of sterility and cGMP deviations observed at the manufacturing site.Wuxi Medical lnstrument Factory Co., Ltd. · D-0247-2025Class IICompletedMar 5, 2025Estradiol GelDefective Container: Some packets may not be fully sealed, potentially allowing for loss of Ethanol from the product.Padagis US LLC · D-0246-2025Class IOngoingFeb 26, 2025Fentanyl Transdermal System CIIDefective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.Alvogen, Inc · D-0245-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0244-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0243-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0242-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0241-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0240-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0239-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0238-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0237-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0236-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0235-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0234-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0233-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0232-2025Class IIOngoingFeb 26, 2025Atomoxetine CapsulesCGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.Glenmark Pharmaceuticals Inc., USA · D-0231-2025Class IOngoingFeb 26, 2025Phenylephrine HCl InjectionPresence of Particulate Matter.Provepharm Inc. · D-0230-2025Class IIOngoingFeb 26, 2025Silodosin CapsulesSubpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 105%)AvKARE · D-0229-2025Class IIOngoingFeb 26, 2025Lorazepam TabletsFailed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0228-2025Class IIOngoingFeb 26, 2025Lorazepam TabletsFailed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0227-2025Class IIOngoingFeb 26, 2025Lorazepam TabletsFailed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0226-2025Class IICompletedFeb 26, 2025fentaNYL Citrate In Sodium Chloride 1600mcg/100mLLack of Assurance of SterilityFagron Compounding Services · D-0225-2025Class IIOngoingFeb 19, 2025Irbesartan Tablets USPOut of Specification for DissolutionAvKARE · D-0224-2025Class IOngoingFeb 12, 2025Adrenalin Chloride SolutionLabeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP)ENDO USA, Inc. · D-0223-2025Class IIITerminatedFeb 12, 2025Guaifenesin and Codeine Phosphate Oral Solution USPSuperpotent; sodium benzoate preservativePAI Holdings, LLC. dba Pharmaceutical Associates Inc · D-0222-2025Class IIOngoingFeb 12, 2025Potassium Chloride Extended-Release TabletsFailed Dissolution Specifications.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0221-2025Class IIOngoingFeb 12, 2025HydrALAZINE HydrochlorideFailed Impurities/Degradation SpecificationsSky Packaging · D-0220-2025Class IIOngoingFeb 12, 2025HydrALAZINE HydrochlorideFailed Impurities/Degradation SpecificationsSky Packaging · D-0219-2025Class IIOngoingFeb 12, 2025Granix (tbo-filgrastim) Injection 300 mcg/0.5 mLFailed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limitTeva Pharmaceuticals USA, Inc · D-0218-2025Class IITerminatedFeb 12, 2025Carvedilol 25 mg TabletCGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.RemedyRepack Inc. · D-0217-2025

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.